There are multiple exchange traded funds addressing the lucrative genomics segment, but the real star of the group is the ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG). ARKG includes companies that merge healthcare with technology to capitalize on the revolution in genomic sequencing.
